title: Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age.
abstract: BACKGROUND
  Information has been very limited on the pharmacokinetics of the selective alpha(2)-adrenoceptor agonist dexmedetomidine in children, particularly in children <2 yr of age.
  
  
  METHODS
  Eight children aged between 28 days and 23 months and eight children aged between 2 and 11 yr undergoing either elective bronchoscopy or nuclear magnetic resonance imaging were included in the study. Dexmedetomidine 1 microg kg(-1) was infused i.v. over 5 min. Blood samples for the measurement of plasma concentrations of dexmedetomidine were collected for 5 h after starting the infusion. Pharmacokinetic calculations were based on non-compartmental methods.
  
  
  RESULTS
  In the two groups of paediatric patients, the median (range) values for total plasma clearance of dexmedetomidine were 17.4 (14.1-27.6) and 17.3 (9.3-22.5) ml kg(-1) min(-1), for volume of distribution at steady state 3.8 (1.9-4.6) and 2.2 (1.3-2.8) litre kg(-1) (P<0.05), and for elimination half-life 139 (90-198) and 96 (69-140) min (P<0.05), respectively. The volume of distribution at steady state was negatively associated with subject age (r=-0.69, P<0.05).
  
  
  CONCLUSIONS
  To reach a certain plasma concentration, children younger than 2 yr of age evidently need larger initial doses of dexmedetomidine than the older children, as young children have a larger volume of distribution of the drug than older children and adults. Since the total plasma clearance of dexmedetomidine is independent of age, similar rates of infusion can be used in younger and older children to maintain a steady-state concentration of dexmedetomidine in plasma.
authors: Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Unit, Turku University Hospital, PO Box 52, FIN-20521 Turku, Finland. sanna.vilo@tyks.fi
authors: S
authors: S
authors: Vilo
authors: P
authors: P
authors: Rautiainen
authors: K
authors: K
authors: Kaisti
authors: R
authors: R
authors: Aantaa
authors: M
authors: M
authors: Scheinin
authors: T
authors: T
authors: Manner
authors: K T
authors: KT
authors: Olkkola
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000097:blood*; D000375:Aging / Q000097:blood; D001999:Bronchoscopy; D002648:Child; D002675:Child, Preschool; D016292:Procedural Sedation / Q000379:methods; D020927:Dexmedetomidine / Q000008:administration & dosage / Q000097:blood*; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000097:blood*; D007223:Infant; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D009682:Magnetic Resonance Spectroscopy; D008297:Male
chemical_list: D000316:Adrenergic alpha-Agonists; D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine